Propofol ameliorates doxorubicin-induced oxidative stress and cellular apoptosis in rat cardiomyocytes

Toxicology and Applied Pharmacology

Volumn 257, Issue 3, 2011, Pages 437-448

  Lai, H C ^a,b   Yeh, Y C ^c   Wang, L C ^a   Ting, C T ^a,b   Lee, W L ^a,b   Lee, H W ^a   Wang, K Y ^a,d   Wu, A ^e   Su, C S ^a,b   Liu, T J ^a,b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NANHUA UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Doxorubicin; Heart; Oxidative stress; Propofol

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; COPPER ZINC SUPEROXIDE DISMUTASE; DOXORUBICIN; DRUG VEHICLE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE PEROXIDASE 2; MANGANESE SUPEROXIDE DISMUTASE; OXIDOREDUCTASE; PROPOFOL; PROTEIN KINASE C DELTA; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TRYPAN BLUE; ANTINEOPLASTIC ANTIBIOTIC; ANTIOXIDANT; INTRAVENOUS ANESTHETIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ASSAY; CELL CULTURE; CELL VIABILITY; CLINICAL EXAMINATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME ACTIVITY; HEART MUSCLE CELL; INTRACELLULAR SIGNALING; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NITRATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; RAT; ANIMAL; CELL SURVIVAL; DRUG EFFECT; METABOLISM; NEWBORN; PATHOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANESTHETICS, INTRAVENOUS; ANIMALS; ANIMALS, NEWBORN; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; DOXORUBICIN; MEMBRANE POTENTIAL, MITOCHONDRIAL; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROPOFOL; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84855734341     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.10.001     Document Type: Article

References (55)

1. Aldieri E., Bergandi L., Riganti C., Costamagna C., Bosia A., Ghigo D. Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation. Toxicol. Appl. Pharmacol. 2002, 185:85-90.
2. Allaouchiche B., Debon R., Goudable J., Chassard D., Duflo F. Oxidative stress status during exposure to propofol, sevoflurane and desflurane. Anesth. Analg. 2001, 93:981-985.
3. Alshabanah O.A., Hafez M.M., Al-Harbi M.M., Hassan Z.K., Al Rejaie S.S., Asiri Y.A., Sayed-Ahmed M.M. Doxorubicin toxicity can be ameliorated during antioxidant l-carnitine supplementation. Oxid. Med. Cell. Longev. 2010, 3:428-433.
4. Baliga B., Kumar S. Apaf-1/cytochrome c apoptosome: an essential initiator of caspase activation or just a sideshow?. Cell Death Differ. 2003, 10:16-18.
5. Basu A. Involvement of protein kinase C-delta in DNA damage-induced apoptosis. J. Cell. Mol. Med. 2003, 7:341-350.
6. Branca D., Roberti M.S., Lorenzin P., Vincenti E., Scutari G. Influence of the anesthetic 2,6-diisopropylphenol on the oxidative phosphorylation of isolated rat liver mitochondria. Biochem. Pharmacol. 1991, 42:87-90.
7. Breckenridge D.G., Xue D. Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. Curr. Opin. Cell Biol. 2004, 16:647-652.
8. Chaiswing L., Cole M.P., St Clair D.K., Ittarat W., Szweda L.I., Oberley T.D. Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury. Toxicol. Pathol. 2004, 32:536-547.
9. Childs A.C., Phaneuf S.L., Dirks A.J., Phillips T., Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res. 2002, 62:4592-4598.
10. Choi S.U., Lee H.W., Lim H.J., Yoon S.M., Chang S.H. The effects of propofol on cardiac function after 4hours of cold cardioplegia and reperfusion. J. Cardiothorac. Vasc. Anesth. 2007, 21:678-682.
11. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J. 1999, 341(Pt 2):233-249.
12. Das J., Ghosh J., Manna P., Sil P.C. Taurine suppresses doxorubicin-triggered oxidative stress and cardiac apoptosis in rat via up-regulation of PI3-K/Akt and inhibition of p53, p38-JNK. Biochem. Pharmacol. 2011, 81:891-909.
13. De La Cruz J.P., Villalobos M.A., Sedeno G., Sanchez De La Cuesta F. Effect of propofol on oxidative stress in an in vitro model of anoxia-reoxygenation in the rat brain. Brain Res. 1998, 800:136-144.
14. Green T.R., Bennett S.R., Nelson V.M. Specificity and properties of propofol as an antioxidant free radical scavenger. Toxicol. Appl. Pharmacol. 1994, 129:163-169.
15. Han X., Pan J., Ren D., Cheng Y., Fan P., Lou H. Naringenin-7-O-glucoside protects against doxorubicin-induced toxicity in H9c2 cardiomyocytes by induction of endogenous antioxidant enzymes. Food Chem. Toxicol. 2008, 46:3140-3146.
16. Javadov S.A., Lim K.H., Kerr P.M., Suleiman M.S., Angelini G.D., Halestrap A.P. Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition. Cardiovasc. Res. 2000, 45:360-369.
17. Jin Y.C., Kim W., Ha Y.M., Shin I.W., Sohn J.T., Kim H.J., Seo H.G., Lee J.H., Chang K.C. Propofol limits rat myocardial ischemia and reperfusion injury with an associated reduction in apoptotic cell death in vivo. Vascul. Pharmacol. 2009, 50:71-77.
18. Kim H.S., Chang W.C., Hwang K.C., Choi I.G., Park W.K. Effect of propofol on calcium homeostasis in hypoxia-reoxygenated neonatal rat cardiomyocytes. Eur. J. Pharmacol. 2008, 594:139-145.
19. Ko S.H., Yu C.W., Lee S.K., Choe H., Chung M.J., Kwak Y.G., Chae S.W., Song H.S. Propofol attenuates ischemia-reperfusion injury in the isolated rat heart. Anesth. Analg. 1997, 85:719-724.
20. Kokita N., Hara A. Propofol attenuates hydrogen peroxide-induced mechanical and metabolic derangements in the isolated rat heart. Anesthesiology 1996, 84:117-127.
21. Lai H.C., Liu T.J., Ting C.T., Sharma P.M., Wang P.H. Insulin-like growth factor-1 prevents loss of electrochemical gradient in cardiac muscle mitochondria via activation of PI 3 kinase/Akt pathway. Mol. Cell. Endocrinol. 2003, 205:99-106.
22. Lai H.C., Liu T.J., Ting C.T., Yang J.Y., Huang L., Wallace D., Kaiser P., Wang P.H. Regulation of IGF-I receptor signaling in diabetic cardiac muscle: dysregulation of cytosolic and mitochondria HSP60. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E292-E297.
23. Lai H.C., Yeh Y.C., Ting C.T., Lee W.L., Lee H.W., Wang L.C., Wang K.Y., Lai H.C., Wu A., Liu T.J. Doxycycline suppresses doxorubicin-induced oxidative stress and cellular apoptosis in mouse hearts. Eur. J. Pharmacol. 2010, 644:176-187.
24. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
25. Liu T.J., Yeh Y.C., Ting C.T., Lee W.L., Wang L.C., Lee H.W., Wang K.Y., Lai H.C., Lai H.C. Ginkgo biloba extract 761 reduces doxorubicin-induced apoptotic damage in rat hearts and neonatal cardiomyocytes. Cardiovasc. Res. 2008, 80:227-235.
26. Marik P.E. Propofol: an immunomodulating agent. Pharmacotherapy 2005, 25:28S-33S.
27. Menku A., Ogden M., Saraymen R. The protective effects of propofol and citicoline combination in experimental head injury in rats. Turk. Neurosurg. 2010, 20:57-62.
28. Muller I., Jenner A., Bruchelt G., Niethammer D., Halliwell B. Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem. Biophys. Res. Commun. 1997, 230:254-257.
29. Murphy P.G., Bennett J.R., Myers D.S., Davies M.J., Jones J.G. The effect of propofol anaesthesia on free radical-induced lipid peroxidation in rat liver microsomes. Eur. J. Anaesthesiol. 1993, 10:261-266.
30. Nguyen L.T., Rebecchi M.J., Moore L.C., Glass P.S., Brink P.R., Liu L. Attenuation of isoflurane-induced preconditioning and reactive oxygen species production in the senescent rat heart. Anesth. Analg. 2008, 107:776-782.
31. 2-treated bovine endothelial cells. Free Radic. Res. 2002, 36:1147-1153.
32. Ozturk E., Demirbilek S., Kadir But A., Saricicek V., Gulec M., Akyol O., Ozcan Ersoy M. Antioxidant properties of propofol and erythropoietin after closed head injury in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:922-927.
33. Park B.S., Song Y.S., Yee S.B., Lee B.G., Seo S.Y., Park Y.C., Kim J.M., Kim H.M., Yoo Y.H. Phospho-ser 15-p53 translocates into mitochondria and interacts with Bcl-2 and Bcl-xL in eugenol-induced apoptosis. Apoptosis 2005, 10:193-200.
34. Peshavariya H.M., Dusting G.J., Selemidis S. Analysis of dihydroethidium fluorescence for the detection of intracellular and extracellular superoxide produced by NADPH oxidase. Free Radic. Res. 2007, 41:699-712.
35. Reeve J.L., Szegezdi E., Logue S.E., Chonghaile T.N., O'Brien T., Ritter T., Samali A. Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL. J. Cell. Mol. Med. 2007, 11:509-520.
36. Schaer H. Propofol infusion for the maintenance of short-term anesthesia. Anaesthesist 1988, 37:187-192.
37. Schmidt H.H., Walter U. NO at work. Cell 1994, 78:919-925.
38. Shimono H., Goromaru T., Kadota Y., Tsurumaru T., Kanmura Y. Propofol displays no protective effect against hypoxia/reoxygenation injury in rat liver slices. Anesth. Analg. 2003, 97:442-448. (table of contents).
39. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 1998, 339:900-905.
40. Singal P.K., Li T., Kumar D., Danelisen I., Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol. Cell. Biochem. 2000, 207:77-86.
41. Sztark F., Ichas F., Ouhabi R., Dabadie P., Mazat J.P. Effects of the anaesthetic propofol on the calcium-induced permeability transition of rat heart mitochondria: direct pore inhibition and shift of the gating potential. FEBS Lett. 1995, 368:101-104.
42. Takizawa D., Sato E., Nishikawa K., Hinohara H., Hiraoka H., Saito S., Goto F., Kunimoto F. Plasma concentration for optimal sedation and total body clearance of propofol in patients after esophagectomy. J. Anesth. 2005, 19:88-90.
43. Tramer M., Moore A., McQuay H. Meta-analytic comparison of prophylactic antiemetic efficacy for postoperative nausea and vomiting: propofol anaesthesia vs omitting nitrous oxide vs total i.v. anaesthesia with propofol. Br. J. Anaesth. 1997, 78:256-259.
44. Tramer M., Moore A., McQuay H. Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies. Br. J. Anaesth. 1997, 78:247-255.
45. Tsuchiya M., Asada A., Arita K., Utsumi T., Yoshida T., Sato E.F., Utsumi K., Inoue M. Induction and mechanism of apoptotic cell death by propofol in HL-60 cells. Acta Anaesthesiol. Scand. 2002, 46:1068-1074.
46. Wang B., Shravah J., Luo H., Raedschelders K., Chen D.D., Ansley D.M. Propofol protects against hydrogen peroxide-induced injury in cardiac H9c2 cells via Akt activation and Bcl-2 up-regulation. Biochem. Biophys. Res. Commun. 2009, 389:105-111.
47. Wong H.L., Rauth A.M., Bendayan R., Manias J.L., Ramaswamy M., Liu Z., Erhan S.Z., Wu X.Y. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm. Res. 2006, 23:1574-1585.
48. Xia Z., Godin D.V., Chang T.K., Ansley D.M. Dose-dependent protection of cardiac function by propofol during ischemia and early reperfusion in rats: effects on 15-F2t-isoprostane formation. Can. J. Physiol. Pharmacol. 2003, 81:14-21.
49. Xia Z., Huang Z., Ansley D.M. Large-dose propofol during cardiopulmonary bypass decreases biochemical markers of myocardial injury in coronary surgery patients: a comparison with isoflurane. Anesth. Analg. 2006, 103:527-532.
50. Xia W.F., Liu Y., Zhou Q.S., Tang Q.Z., Zou H.D. Comparison of the effects of propofol and midazolam on inflammation and oxidase stress in children with congenital heart disease undergoing cardiac surgery. Yonsei Med. J. 2011, 52:326-332.
51. Xu J.J., Wang Y.L. Propofol attenuation of hydrogen peroxide-mediated oxidative stress and apoptosis in cultured cardiomyocytes involves haeme oxygenase-1. Eur. J. Anaesthesiol. 2008, 25:395-402.
52. Yang J., Li T.Z., Zhang B.X. Effects of propofol on the anoxic/reoxygen responses by c-fos and apoptosis in primary cultured hippocampal neurons. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2004, 20:49-57.
53. Yoo K.Y., Yang S.Y., Lee J., Im W.M., Jeong C.Y., Chung S.S., Kwak S.H. Intracoronary propofol attenuates myocardial but not coronary endothelial dysfunction after brief ischaemia and reperfusion in dogs. Br. J. Anaesth. 1999, 82:90-96.
54. Yue H., Uzui H., Shimizu H., Nakano A., Mitsuke Y., Ueda T., Lee J.D. Different effects of calcium channel blockers on matrix metalloproteinase-2 expression in cultured rat cardiac fibroblasts. J. Cardiovasc. Pharmacol. 2004, 44:223-230.
55. Zhu B., Ye T.H., Zhao J.X. Protective effect of propofol at clinically relevant concentrations on primary cultured newborn rat hippocampus. Chin. Med. J. (Engl.) 2005, 118:603-605.